536 related articles for article (PubMed ID: 37504358)
21. Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events.
Yan T; Yu L; Zhang J; Chen Y; Fu Y; Tang J; Liao D
Front Immunol; 2024; 15():1292122. PubMed ID: 38410506
[TBL] [Abstract][Full Text] [Related]
22. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
[TBL] [Abstract][Full Text] [Related]
23. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
24. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
25. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
26. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
Hall KH; Liu Y; Jiang C; Harvey RD
Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
[TBL] [Abstract][Full Text] [Related]
27. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
Das S; Johnson DB
J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
29. Time to dissect the autoimmune etiology of cancer antibody immunotherapy.
Dougan M; Pietropaolo M
J Clin Invest; 2020 Jan; 130(1):51-61. PubMed ID: 31895048
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
32. Autoimmune complications of immunotherapy: pathophysiology and management.
Chan KK; Bass AR
BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
34. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
35. Immune-related adverse events of immune checkpoint inhibitors: a brief review.
Myers G
Curr Oncol; 2018 Oct; 25(5):342-347. PubMed ID: 30464684
[TBL] [Abstract][Full Text] [Related]
36. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
37. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
Wang W; Gu X; Wang L; Pu X; Feng H; Xu C; Lou G; Shao L; Xu Y; Wang Q; Wang S; Gao W; Zhang Y; Song Z
Cancer Immunol Immunother; 2022 Jul; 71(7):1693-1703. PubMed ID: 34817639
[TBL] [Abstract][Full Text] [Related]
38. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
39. Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade.
Hu W; Wang G; Wang Y; Riese MJ; You M
iScience; 2020 Oct; 23(10):101580. PubMed ID: 33083746
[TBL] [Abstract][Full Text] [Related]
40. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.
Del Gaudio A; Di Vincenzo F; Petito V; Giustiniani MC; Gasbarrini A; Scaldaferri F; Lopetuso LR
Inflamm Bowel Dis; 2024 Jun; 30(6):1018-1031. PubMed ID: 37801695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
